NCT04568772CompletedPhase 1
A Randomized, Open-label, Three-period Crossover Clinical Trial to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers
Seoul National University Hospital1 site in 1 country19 target enrollmentStarted: November 25, 2020Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 19
- Locations
- 1
- Primary Endpoint
- AUClast of proguanil, cycloguanil
Study Overview
Brief Summary
The aim of this study is to evaluate the influence of tegoprazan on the pharmacokinetics of proguanil in healthy volunteers.
Detailed Description
Evaluation criteria
- Pharmacokinetic assessment with plasma concentrations of proguanil and cycloguanil
- Safety assessments with adverse event monitoring including subjective/objective symptoms, physical examination, vital signs, electrocardiogram, and laboratory tests
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 19 Years to 50 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Healthy adult aged ≥ 19 years and ≤ 50 years at the time of screening
- •Body weight of ≥ 55.0 kg and ≤ 90.0 kg, with body mass index (BMI) of ≥ 19.0 kg/m2 and ≤ 30.0 kg/m2 at the time of screening
- •Extensive metabolizer (*1/*1) by CYP2C19 genotyping
- •A subject without any congenital or chronic disease, and has no medical examination result as pathological symptoms or signs
- •A subject who listened to sufficient explanation and fully understood this study, and voluntarily decided to participate and agreed in writing to comply with the precautions
- •A subject determined eligible for this study by investigator based physical examination, clinical laboratory tests, interview, etc.
Exclusion Criteria
- •A subject with clinically significant hepatobiliary (severe hepatic impairment, etc.), renal (severe renal impairment, etc.), neurologic, immunologic, respiratory, gastrointestinal, endocrine, blood•oncology, cardiovascular (heart failure, Torsades de pointes, etc.), urinary, or, psychical diseases (except for simple dental past history such as tartar, impacted tooth, or wisdom tooth) or a history
- •A subject who has hypersensitivity to the investigational products, drugs containing the same class, or other drugs (penicillin and antibiotics, etc.), or a history of clinically significant hypersensitivity
- •A subject with a history of gastrointestinal disorders (gastrointestinal ulcer, gastritis, gastrospasm, gastroesophageal reflux disease, Crohn's disease, etc.) or surgery (except for simple appendectomy and herniotomy) that may affect the safety and pharmacokinetics of the investigational products
- •A subject with the following results in the screening test:
- •Blood AST (GOT), ALT (GPT): > Normal range upper × 1.5
- •Creatinine clearance calculated by MDRD equation: < 80mL/min
- •QTc interval: > 450 ms
- •Fasting serum glucose: > 126 mg/dL
- •Positive serological test (syphilis test, hepatitis B test, hepatitis C test, human immunodeficiency virus (HIV) test)
- •A subject with systolic blood pressure < 90 mmHg or > 150 mmHg, or diastolic blood pressure < 50 mmHg or > 100 mmHg when vital signs are measured in sitting position after resting for at least 3 minutes
- •A subject with a history of or positive urine screening for drug abuse
- •A subject who administered any prescription drugs or herbal medicine within 2 weeks prior to the expected date of the first dose, or any over-the-counter drug (OTC drug, health functional food or vitamin within 1 week prior to the expected date of the first dose (However, can participate in the study if otherwise decided eligible by the investigator), or is expected to administer it
- •A subject who administered drugs that induce or inhibit the drug metabolizing enzymes, such as barbitals, within 1 week prior to the expected date of the first dose
- •A subject who participated in other clinical trial or bioequivalence study within 6 months prior to the expected date of the first dose
- •A subject who donated whole blood within 2 months or the component blood within 1 month prior to the expected date of the first dose, or received blood transfusion within 1 month prior to the expected date of the first dose
- •A subject with persistent alcohol intake (> 21 units/week, 1 unit = 10 g of pure alcohol), or inability to abstain from drinking from 3 days before the expected date of the first dose until the last discharge
- •A subject who is a currently smoker (But, can be eligible if he or she quitted smoking 3 months ago), or is not able to cease smoking from 3 months before the expected date of the first dose until the last discharge
- •A subject with inability to refrain from grapefruit-containing food from 3 days before the expected date of the first dose until the last discharge
- •A subject with excessive caffeine intake (> 5 units/day), or inability to refrain from caffeine or caffeine-containing food from 3 days before the expected date of the first dose until the last discharge
- •A subject with inability to use a medically acceptable double contraception or contraception throughout the study and for at least 4 weeks after the last dose, and with inability to agree to donate sperm until the period
Arms & Interventions
Atovaquone/Proguanil 250/100 mg
Active Comparator
A single oral administration of atovaquone/proguanil 250/100 mg
Intervention: Atovaquone / Proguanil 250/100 mg (Drug)
Tegoprazan 50 mg + Atovaquone/Proguanil 250/100 mg
Experimental
Oral administration of tegoprazan 50 mg once daily for 6 days and then co-administration of tegoprazan 50 mg and atovaquone/proguanil 250/100 mg at 7 day
Intervention: Atovaquone / Proguanil 250/100 mg (Drug)
Tegoprazan 50 mg + Atovaquone/Proguanil 250/100 mg
Experimental
Oral administration of tegoprazan 50 mg once daily for 6 days and then co-administration of tegoprazan 50 mg and atovaquone/proguanil 250/100 mg at 7 day
Intervention: Tegoprazan 50 mg (Drug)
Esomeprazole 40 mg + Atovaquone/Proguanil 250/100 mg
Experimental
Oral administration of esomeprazole 40 mg once daily for 6 days and then co-administration of esomeprazole 40 mg and atovaquone/proguanil 250/100 mg at 7 day
Intervention: Atovaquone / Proguanil 250/100 mg (Drug)
Esomeprazole 40 mg + Atovaquone/Proguanil 250/100 mg
Experimental
Oral administration of esomeprazole 40 mg once daily for 6 days and then co-administration of esomeprazole 40 mg and atovaquone/proguanil 250/100 mg at 7 day
Intervention: Esomeprazole 40 mg (Drug)
Vonoprazan 20 mg + Atovaquone/Proguanil 250/100 mg
Experimental
Oral administration of vonoprazan 20 mg once daily for 6 days and then co-administration of vonoprazan 20 mg and atovaquone/proguanil 250/100 mg at 7 day
Intervention: Atovaquone / Proguanil 250/100 mg (Drug)
Vonoprazan 20 mg + Atovaquone/Proguanil 250/100 mg
Experimental
Oral administration of vonoprazan 20 mg once daily for 6 days and then co-administration of vonoprazan 20 mg and atovaquone/proguanil 250/100 mg at 7 day
Intervention: Vonoprazan 20 mg (Drug)
Outcomes
Primary Outcomes
AUClast of proguanil, cycloguanil
Time Frame: Pre-dose(0 hour) and up to 48 hours in each period
Systemic exposure of proguanil and cycloguanil
Secondary Outcomes
- Cmax of proguanil(Pre-dose(0 hour) and up to 48 hours in each period)
- AUCinf of proguanil(Pre-dose(0 hour) and up to 48 hours in each period)
- Tmax of proguanil(Pre-dose(0 hour) and up to 48 hours in each period)
- CLR of proguanil(Pre-dose(0 hour) and up to 48 hours in each period)
- CL/F of proguanil(Pre-dose(0 hour) and up to 48 hours in each period)
- fe of proguanil(Pre-dose(0 hour) and up to 48 hours in each period)
- t1/2 of proguanil(Pre-dose(0 hour) and up to 48 hours in each period)
- Vz/F of proguanil(Pre-dose(0 hour) and up to 48 hours in each period)
Investigators
SeungHwan Lee
Clinical Associate Professor
Seoul National University Hospital
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 1
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy ControlsHepatic ImpairmentHealthyNCT04494269HK inno.N Corporation28
Completed
Phase 1
Study to Evaluate the Pharmacodynamics After Single Oral Dosing of Tegoprazan, EAPA115 and RAPA115 in Healthy VolunteersHealthyNCT04231136HK inno.N Corporation19
Completed
Phase 1
Effect of Tegoprazan or RAPA113 on Pharmacodynamics/Pharmacokinetics of Clopidogrel in Healthy Male VolunteersHealthyNCT04171687HK inno.N Corporation36
Completed
Phase 1
Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male ParticipantsHealthyNCT03814642HK inno.N Corporation25
Completed
Phase 1
Effect of Tegoprazan or RAPA114 on Pharmacokinetic of Atorvastatin in Healthy Adult VolunteersHealthyNCT04221321HK inno.N Corporation32